NK cell levels predict disease activity in patients with Multiple Sclerosis on Ocrelizumab/Rituximab therapy

被引：0
|
作者：
Dal Bello, Simone [1 ]
Lorenzut, Simone [2 ]
Saccomano, Emma [3 ]
Tereshko, Yan [1 ]
Cargnelutti, Daniela [2 ]
Cutuli, Daniela [2 ]
Gigli, Gian Luigi [3 ]
Valente, Mariarosaria [1 ,3 ]
机构：
[1] Hosp Santa Maria Misericordia, Clin Neurol, Udine, Italy
[2] Hosp Santa Maria Misericordia, Neurol, Udine, Italy
[3] Univ Udine, Dipartiment Med, Dipartimento Area Med, Univ Fruil, Udine, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1483/2062
引用
收藏
页码：944 / 945
页数：2
相关论文
共 50 条
  • [21] Duration of B-cell depletion in patients receiving ocrelizumab or rituximab for Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorders
    AbdelRazek, M. A.
    Casasola, M.
    Mollashahi, R.
    Brodski, A.
    Morin, S.
    Augustynowicz, A.
    Jassim, S.
    Matiello, M.
    Sloane, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 100 - 100
  • [22] Ocrelizumab: a new milestone in multiple sclerosis therapy
    Mulero, Patricia
    Midaglia, Luciana
    Montalban, Xavier
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [23] Evaluation of immunoglobulin levels and COVID-19 disease course in patients with multiple sclerosis under ocrelizumab therapy: a tertiary center experience
    Arslan, D.
    Acar-Ozen, N. P.
    Tuncer, A.
    Karabudak, R.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 589 - 590
  • [24] Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis
    Graille-Avy, Lisa
    Boutiere, Clemence
    Rigollet, Camille
    Perriguey, Marine
    Rico, Audrey
    Demortiere, Sarah
    Durozard, Pierre
    Hilezian, Frederic
    Vely, Frederic
    Bertault-Peres, Pierre
    Pelletier, Jean
    Maarouf, Adil
    Audoin, Bertrand
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2024, 11 (03): : e200231
  • [25] Comparison of Ocrelizumab and Rituximab over Two Years of Treatment for Multiple Sclerosis
    Vollmer, B.
    Nair, K.
    Sillau, S.
    Corboy, J. R.
    Alvarez, E.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 92 - 93
  • [26] B-Cell repopulation after Ocrelizumab in Multiple Sclerosis Patients
    Moswela, Olivia
    Hadley, Gina
    De Luca, Gabriele
    NEUROLOGY, 2021, 96 (15)
  • [27] The impact of changing from ocrelizumab to ofatumumab on disease activity, infection and immunological parameters in patients with multiple sclerosis
    Montague, Turlough
    Chatterton, Sophie
    Cheung, Emily
    Thomas, Karen
    Simpson-Burke, Nicole
    Markoulis, Katherine
    Miller, Celia
    Fontes-Villalba, Ariadna
    Parratt, John
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1084 - 1084
  • [28] Effect of rituximab on immunoglobulin levels in pediatric multiple sclerosis patients
    Mehta, N.
    Balasa, A.
    Shukla, N.
    Fisher, K.
    Lotze, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 627 - 628
  • [29] Effect of Rituximab on Immunoglobulin levels in Pediatric Multiple Sclerosis Patients
    Mehta, Natasha
    Balasa, Alfred
    Shukla, Nikita
    Fisher, Kristen
    Lotze, Timothy
    NEUROLOGY, 2021, 96 (15)
  • [30] Disease activity in multiple sclerosis patients switching from fingolimod to cladribine compared to rituximab
    Nygaard, G. O.
    Torgauten, H.
    Skattebol, L.
    Hogestol, E. A.
    Sowa, P.
    Myhr, K. -M.
    Torkildsen, O. F.
    Celius, E. G.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 568 - 569
12345